EUVIMEDEUVIMED entdecken
CrossrefInfokarte

ZYS-1 is not an ADAR1 inhibitor

Cassandra N. Smoak, Estelle N. Gardner, Renee N. Chua, Kyle A. Cottrell

RNA · 2025-12 · 31 (12) · 1703-1711

DOI: 10.1261/rna.080721.125 ↗
AbstractBibliografische Angaben

Abstract

Adenosine deaminase acting on RNA 1 (ADAR1) edits double-stranded RNA (dsRNA) substrates by the deamination of adenosine to inosine in a process known as A-to-I editing. Modulation of ADAR1 expression and editing activity has previously been described to play a role in cancer development and progression, with upregulation of ADAR1 being observed in a range of cancers. Further, depletion of ADAR1 leads to increased sensing of endogenous dsRNAs by dsRNA sensors in cell lines that require ADAR1 for survival, which are termed ADAR1-dependent. The activation of these sensors induces downstream production of type I interferons as well as translational inhibition and apoptosis. Therefore, ADAR1 is a promising oncologic therapeutic target. Recently, the small molecule ZYS-1 has been developed and presented as a direct inhibitor of ADAR1. We performed a series of in vitro and cellular experiments to validate the efficacy and specificity of ZYS-1 as an ADAR1 inhibitor. Evaluating the effect of ZYS-1 on cell viability revealed it to be equally cytotoxic to both ADAR1-dependent and ADAR1-independent cell lines, as well as wild-type and ADAR1 knockout cells. Moreover, ZYS-1 treatment had little effect on activation of PKR or induction of IFN stimulated genes. Importantly, treatment with ZYS-1 did not reduce cellular A-to-I editing for several known ADAR1 editing sites and did not inhibit in vitro A-to-I editing by recombinant ADAR1. Together, these data indicate that ZYS-1 is not a selective inhibitor of ADAR1.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →